We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Reports Q2 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended June 2023, Pfizer (PFE - Free Report) reported revenue of $12.73 billion, down 54.1% over the same period last year. EPS came in at $0.67, compared to $2.04 in the year-ago quarter.
The reported revenue represents a surprise of -2.03% over the Zacks Consensus Estimate of $13 billion. With the consensus EPS estimate being $0.56, the EPS surprise was +19.64%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Oncology- Ibrance; United States: $850 million versus the four-analyst average estimate of $873.81 million. The reported number represents a year-over-year change of -2.1%.
Revenues- Specialty Care- Xeljanz- Total International: $136 million compared to the $158.75 million average estimate based on four analysts. The reported number represents a change of -22.7% year over year.
Revenues- Specialty Care- Inflectra- United States: $15 million versus $73.57 million estimated by four analysts on average.
Revenues- Specialty Care- Inflectra- Total International: $59 million compared to the $57.04 million average estimate based on four analysts.
Revenues- Oncology- Worldwide: $2.96 billion versus $3.15 billion estimated by four analysts on average.
Revenues- Primary Care- Prevnar family- Worldwide: $1.39 billion versus $1.50 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.
Revenues- Primary Care- Premarin family- Worldwide: $95 million compared to the $104.79 million average estimate based on four analysts. The reported number represents a change of -17.4% year over year.
Revenues- Specialty Care- Inflectra- Worldwide: $74 million versus the four-analyst average estimate of $130.60 million.
Revenues- Oncology- Ibrance- Worldwide: $1.25 billion versus the four-analyst average estimate of $1.29 billion. The reported number represents a year-over-year change of -5.5%.
Revenues- Primary Care- Eliquis alliance revenues and direct sales- Worldwide: $1.76 billion versus the four-analyst average estimate of $1.86 billion. The reported number represents a year-over-year change of +1%.
Revenues- Pfizer CentreOne- Worldwide: $306 million compared to the $312.21 million average estimate based on four analysts.
Revenues- Specialty Care- Vyndaqel family- Worldwide: $782 million versus $722.35 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +41.7% change.
Shares of Pfizer have returned -1.6% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended June 2023, Pfizer (PFE - Free Report) reported revenue of $12.73 billion, down 54.1% over the same period last year. EPS came in at $0.67, compared to $2.04 in the year-ago quarter.
The reported revenue represents a surprise of -2.03% over the Zacks Consensus Estimate of $13 billion. With the consensus EPS estimate being $0.56, the EPS surprise was +19.64%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Pfizer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Oncology- Ibrance; United States: $850 million versus the four-analyst average estimate of $873.81 million. The reported number represents a year-over-year change of -2.1%.
- Revenues- Specialty Care- Xeljanz- Total International: $136 million compared to the $158.75 million average estimate based on four analysts. The reported number represents a change of -22.7% year over year.
- Revenues- Specialty Care- Inflectra- United States: $15 million versus $73.57 million estimated by four analysts on average.
- Revenues- Specialty Care- Inflectra- Total International: $59 million compared to the $57.04 million average estimate based on four analysts.
- Revenues- Oncology- Worldwide: $2.96 billion versus $3.15 billion estimated by four analysts on average.
- Revenues- Primary Care- Prevnar family- Worldwide: $1.39 billion versus $1.50 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.
- Revenues- Primary Care- Premarin family- Worldwide: $95 million compared to the $104.79 million average estimate based on four analysts. The reported number represents a change of -17.4% year over year.
- Revenues- Specialty Care- Inflectra- Worldwide: $74 million versus the four-analyst average estimate of $130.60 million.
- Revenues- Oncology- Ibrance- Worldwide: $1.25 billion versus the four-analyst average estimate of $1.29 billion. The reported number represents a year-over-year change of -5.5%.
- Revenues- Primary Care- Eliquis alliance revenues and direct sales- Worldwide: $1.76 billion versus the four-analyst average estimate of $1.86 billion. The reported number represents a year-over-year change of +1%.
- Revenues- Pfizer CentreOne- Worldwide: $306 million compared to the $312.21 million average estimate based on four analysts.
- Revenues- Specialty Care- Vyndaqel family- Worldwide: $782 million versus $722.35 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +41.7% change.
View all Key Company Metrics for Pfizer here>>>Shares of Pfizer have returned -1.6% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.